Patient Education, Provider Education, and Overall Final Thoughts

A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.

Semaglutide treatment significantly improved quality of life and reduced flare-ups in patients with obesity and hidradenitis suppurativa.

Hilary Baldwin, MD, FAAD, highlighted diagnostic complexities and shared treatment strategies for rosacea in patients with darker skin tones at the Skin of Color Update in New York City last Friday.

Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).

Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and emphasized the importance of clinical trial diversity.